SCHEMBL536092

SCHEMBL536092

Nc1ccc(Cl)nc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.42
MAP2K3 P46734 2/20 0.41
NAPRT Q6XQN6 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GABRP O00591 2/20 0.37
GABRD O14764 2/20 0.37
GABRA1 P14867 2/20 0.37
GABRB1 P18505 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
GABRB2 P47870 2/20 0.37
GABRA4 P48169 2/20 0.37
GABRE P78334 2/20 0.37
GABRA6 Q16445 2/20 0.37
GABRG1 Q8N1C3 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4770758 0.98 TDP1 (0.41) TDP1MAP2K3NAPRTALDH1A1MAPT
SCHEMBL668419 0.83 MAP2K3 (0.53) MAP2K3ALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL7627022 0.82 IKBKB (0.38) MAP2K3ALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL11907148 0.81 MAP2K3 (0.47) TDP1MAP2K3ALDH1A1MAPTSMN1; SMN2
Clopyralid SCHEMBL8535196 0.80 KMT2A (0.50) NAPRTALDH1A1MAPTSMN1; SMN2KMT2A
Clopyralid SCHEMBL29371357 0.80 KMT2A (0.50) NAPRTALDH1A1MAPTSMN1; SMN2KMT2A
Clopyralid SCHEMBL54779 0.80 KMT2A (0.50) NAPRTALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL11263012 0.80 MAPT (0.46) TDP1MAP2K3ALDH1A1MAPTKMT2A
Clopyralid SCHEMBL1698170 0.79 KMT2A (0.47) TDP1NAPRTALDH1A1MAPTKMT2A
SCHEMBL22716315 0.79 CES1 (0.35) TDP1MAP2K3ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055367-A 5-Oxo-4, 5-dihydroimidazo [1,5-a ] quinazoline compounds as PI3K [ alpha ] inhibitors 皮卡维森治疗学股份有限公司 2026-05-15 CN disclosed
US-20250346603-A1 TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIKAVATION THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 US disclosed
US-20250270213-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-08-28 US disclosed
WO-2025101598-A1 BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF ZENO MANAGEMENT, INC. (US) 2025-05-15 WO disclosed
CN-119977893-A Preparation method and application of sulfonamide compound for antagonizing NOD1 清华大学 2025-05-13 CN disclosed
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2025-05-01 US disclosed
CN-119894872-A Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof 修复治疗公司 2025-04-25 CN disclosed
WO-2025085474-A1 5-OXO-4,5-DIHYDROIMIDAZO[1,5-A]QUINAZOLINE COMPOUNDS AS PI3K[ALPHA] INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2025-04-24 WO disclosed
CN-114269720-B Acetyl-coa synthetase short chain2(ACSS2) Small molecule inhibitors of (a) 库拉德夫制药私人有限公司 2025-03-28 CN disclosed
WO-2010007114-A2 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-21 WO disclosed
EP-2144898-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-20 EP disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
US-20090181968-A1 Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides ASTRAZENECA AB (SE) 2009-07-16 US disclosed
US-20090181968-A1 Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides ASTRAZENECA AB (SE) 2009-07-16 US disclosed
US-20090181968-A1 Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides ASTRAZENECA AB (SE) 2009-07-16 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed
CN-101336238-A Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides ASTRAZENECA AB (SE) 2008-12-31 CN disclosed
WO-2008130021-A2 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-30 WO disclosed
WO-2007061360-A2 NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES ASTRAZENECA AB (SE) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME CSNK1A1, CSNK1G1, CSNK2A1 TDP1 533/4885MAP2K3 142/4885NAPRT 1071/4885
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 TDP1 47/4885MAP2K3 1409/4885NAPRT 3194/4885
US-20250346603-A1 TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIK3CA, PIK3CD, PIK3CB TDP1 474/4885MAP2K3 1681/4885NAPRT 889/4885
US-20090181968-A1 Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 TDP1 3454/4885MAP2K3 4223/4885NAPRT 2723/4885
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIK3CA, PIK3CD, PIK3CB TDP1 633/4885MAP2K3 729/4885NAPRT 650/4885
US-20250270213-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 TDP1 801/4885MAP2K3 876/4885NAPRT 1705/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 TDP1 47/4885MAP2K3 1409/4885NAPRT 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.